Payment overview · 2025
General Payments
$1,062.90
48 reported records · 21 companies
Healthcare provider profile · identity verified
Michelle Terwilliger, NP
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · DYER, IN · NPI 1912360546
Verified facts
What the public records show
CMS Open Payments records show Michelle Terwilliger, NP received $1,062.90 in general payments during 2025 across 48 reported records.
Lilly USA, LLC accounted for 16.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 25 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Fycompa, Qulipta, Ubrelvy.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported QULIPTA as an associated drug or biological on 298617 records involving 58957 distinct recipient NPIs. Public Medicare Part D data also shows 72 claims for Qulipta by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Ubrelvy by this doctor in 2024.
Biogen, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TECFIDERA as an associated drug or biological on 28 records involving 22 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Tecfidera by this doctor in 2024.
CATALYST PHARMACEUTICALS, INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FYCOMPA as an associated drug or biological on 3130 records involving 1101 distinct recipient NPIs. Public Medicare Part D data also shows 65 claims for Fycompa by this doctor in 2024.
SK Life Science, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XCOPRI as an associated drug or biological on 1992 records involving 782 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Xcopri by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $171.98 | 16.2% | 5 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $145.48 | 13.7% | 11 | 2025 |
| Alexion Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $85.27 | 8.0% | 3 | 2025 |
| CATALYST PHARMACEUTICALS, INC. | Unresolved — no canonical attribution shown | $83.89 | 7.9% | 3 | 2025 |
| SK Life Science, Inc. |
SK Life Science, Inc. exact · evidence 2025-04-03 |
$65.69 | 6.2% | 3 | 2025 |
| JAZZ PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $56.09 | 5.3% | 2 | 2025 |
| Neurelis, Inc. |
Neurelis, Inc. exact · evidence 2025-02-20 |
$51.89 | 4.9% | 2 | 2025 |
| Biogen, Inc. | Unresolved — no canonical attribution shown | $51.50 | 4.8% | 2 | 2025 |
| MDD US Operations, LLC | Unresolved — no canonical attribution shown | $46.43 | 4.4% | 2 | 2025 |
| Celgene Corporation | Unresolved — no canonical attribution shown | $45.78 | 4.3% | 3 | 2025 |
| EMD Serono, Inc. | Unresolved — no canonical attribution shown | $33.98 | 3.2% | 2 | 2025 |
| Mallinckrodt Hospital Products Inc. | Unresolved — no canonical attribution shown | $29.42 | 2.8% | 1 | 2025 |
| Genentech USA, Inc. | Unresolved — no canonical attribution shown | $27.79 | 2.6% | 1 | 2025 |
| Cycle Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $26.74 | 2.5% | 1 | 2025 |
| TG Therapeutics, Inc. | Unresolved — no canonical attribution shown | $25.88 | 2.4% | 1 | 2025 |
| ARGENX US, INC. | Unresolved — no canonical attribution shown | $21.98 | 2.1% | 1 | 2025 |
| SCILEX PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $21.83 | 2.0% | 1 | 2025 |
| ACADIA Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $19.94 | 1.9% | 1 | 2025 |
| Amneal Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $18.07 | 1.7% | 1 | 2025 |
| HARMONY BIOSCIENCES LLC | Unresolved — no canonical attribution shown | $16.66 | 1.6% | 1 | 2025 |
| Impel Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $16.61 | 1.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,062.90 | 48 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $171.98 | 5 | 2025 |
Source payment records
|
|||||
| ULTOMIRIS Normalized: ultomiris |
Biological | Alexion Pharmaceuticals, Inc. | $85.27 | 3 | 2025 |
Source payment records
|
|||||
| FYCOMPA Normalized: fycompa |
Drug | CATALYST PHARMACEUTICALS, INC. | $83.89 | 3 | 2025 |
Source payment records
|
|||||
| VYALEV Normalized: vyalev |
Drug | ABBVIE INC. | $56.56 | 3 | 2025 |
Source payment records
|
|||||
| EPIDIOLEX Normalized: epidiolex |
Drug | JAZZ PHARMACEUTICALS INC. | $56.09 | 2 | 2025 |
Source payment records
|
|||||
| VALTOCO Normalized: valtoco |
Drug | Neurelis, Inc. | $51.89 | 2 | 2025 |
Source payment records
|
|||||
| BOTOX Normalized: botox |
Biological | ABBVIE INC. | $51.58 | 3 | 2025 |
Source payment records
|
|||||
| VUMERITY Normalized: vumerity |
Drug | Biogen, Inc. | $51.50 | 2 | 2025 |
Source payment records
|
|||||
| Apokyn Normalized: apokyn |
Drug | MDD US Operations, LLC | $46.43 | 2 | 2025 |
Source payment records
|
|||||
| ZEPOSIA Normalized: zeposia |
Drug | Celgene Corporation | $45.78 | 3 | 2025 |
Source payment records
|
|||||
| AMYVID Normalized: amyvid |
Drug | Lilly USA, LLC | $44.36 | 2 | 2025 |
Source payment records
|
|||||
| ACTHAR Normalized: acthar |
Biological | Mallinckrodt Hospital Products Inc. | $29.42 | 1 | 2025 |
Source payment records
|
|||||
| Ocrevus Zunovo Normalized: ocrevus zunovo |
Biological | Genentech USA, Inc. | $27.79 | 1 | 2025 |
Source payment records
|
|||||
| TYSABRI Normalized: tysabri |
Biological | Biogen, Inc. | $27.32 | 1 | 2025 |
Source payment records
|
|||||
| Bafiertam Normalized: bafiertam |
Drug | Cycle Pharmaceuticals Inc | $26.74 | 1 | 2025 |
Source payment records
|
|||||
| BRIUMVI Normalized: briumvi |
Drug | TG Therapeutics, Inc. | $25.88 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $23.13 | 3 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $23.13 | 3 | 2025 |
Source payment records
|
|||||
| VYVGART Normalized: vyvgart |
Drug | ARGENX US, INC. | $21.98 | 1 | 2025 |
Source payment records
|
|||||
| ZTLido Normalized: ztlido |
Drug | SCILEX PHARMACEUTICALS INC. | $21.83 | 1 | 2025 |
Source payment records
|
|||||
| NUPLAZID Normalized: nuplazid |
Drug | ACADIA Pharmaceuticals Inc | $19.94 | 1 | 2025 |
Source payment records
|
|||||
| CREXONT Normalized: crexont |
Drug | Amneal Pharmaceuticals LLC | $18.07 | 1 | 2025 |
Source payment records
|
|||||
| WAKIX Normalized: wakix |
Drug | HARMONY BIOSCIENCES LLC | $16.66 | 1 | 2025 |
Source payment records
|
|||||
| TRUDHESA Normalized: trudhesa |
Drug | Impel Pharmaceuticals LLC | $16.61 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $14.21 | 2 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FYCOMPA fycompa |
2025 | Fycompa | 2024 | 65 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| QULIPTA qulipta |
2025 | Qulipta | 2024 | 72 | exact normalized | Medicare Part D |
| UBRELVY ubrelvy |
2025 | Ubrelvy | 2024 | 44 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | QULIPTA open payments reported associated product |
CMS Open Payments — General Payments 298617 supporting records · 58957 recipient NPIs · example record 1201352530 |
Qulipta · 2024 Exact normalized brand match · 1 Part D row |
72 | 20 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
44 | suppressed by CMS |
| Biogen, Inc. Exact reporting entity; no affiliate inference |
2025 | TECFIDERA open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 22 recipient NPIs · example record 1208304358 |
Tecfidera · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| CATALYST PHARMACEUTICALS, INC. Exact reporting entity; no affiliate inference |
2025 | FYCOMPA open payments reported associated product |
CMS Open Payments — General Payments 3130 supporting records · 1101 recipient NPIs · example record 1253216846 |
Fycompa · 2024 Exact normalized brand match · 1 Part D row |
65 | suppressed by CMS |
| SK Life Science, Inc. Exact reporting entity; no affiliate inference |
2025 | XCOPRI open payments reported associated product |
CMS Open Payments — General Payments 1992 supporting records · 782 recipient NPIs · example record 1252276115 |
Xcopri · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Gabapentin | Gabapentin | 268 | 72 |
| Levetiracetam | Levetiracetam | 168 | 49 |
| Lamotrigine | Lamotrigine | 152 | 36 |
| Donepezil Hcl | Donepezil Hcl | 140 | 65 |
| Pregabalin | Pregabalin | 136 | 37 |
| Duloxetine Hcl | Duloxetine Hcl | 133 | 41 |
| Clonazepam | Clonazepam | 111 | 22 |
| Memantine Hcl | Memantine Hcl | 107 | 44 |
| Oxcarbazepine | Oxcarbazepine | 103 | 17 |
| Nurtec Odt | Rimegepant Sulfate | 93 | 18 |
| Baclofen | Baclofen | 92 | 22 |
| Primidone | Primidone | 89 | 32 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 84 | 33 |
| Lacosamide | Lacosamide | 83 | 12 |
| Sumatriptan Succinate | Sumatriptan Succinate | 82 | 13 |
| Alprazolam | Alprazolam | 73 | 14 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 73 | suppressed |
| Qulipta | Atogepant | 72 | 20 |
| Divalproex Sodium | Divalproex Sodium | 65 | 19 |
| Fycompa | Perampanel | 65 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 64 | 12 |
| Ropinirole Hcl | Ropinirole Hcl | 64 | 16 |
| Sertraline Hcl | Sertraline Hcl | 64 | 23 |
| Emgality Pen | Galcanezumab-Gnlm | 62 | 14 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 61 | 12 |
| Quetiapine Fumarate | Quetiapine Fumarate | 58 | 20 |
| Rivastigmine | Rivastigmine Tartrate | 51 | 22 |
| Aimovig Autoinjector | Erenumab-Aooe | 49 | 11 |
| Tizanidine Hcl | Tizanidine Hcl | 49 | 12 |
| Escitalopram Oxalate | Escitalopram Oxalate | 47 | 11 |
| Trazodone Hcl | Trazodone Hcl | 44 | 13 |
| Ubrelvy | Ubrogepant | 44 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 40 | suppressed |
| Diazepam | Diazepam | 38 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 36 | 12 |
| Fluoxetine Hcl | Fluoxetine Hcl | 36 | suppressed |
| Topiramate | Topiramate | 36 | 11 |
| Risperidone | Risperidone | 29 | suppressed |
| Aptiom | Eslicarbazepine Acetate | 28 | suppressed |
| Lorazepam | Lorazepam | 27 | 20 |
| Ondansetron Hcl | Ondansetron Hcl | 24 | suppressed |
| Vimpat | Lacosamide | 24 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 22 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 22 | suppressed |
| Xcopri | Cenobamate | 22 | suppressed |
| Amantadine | Amantadine Hcl | 21 | suppressed |
| Atorvastatin Calcium | Atorvastatin Calcium | 21 | suppressed |
| Acetazolamide Er | Acetazolamide | 20 | suppressed |
| Clobazam | Clobazam | 20 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 19 | suppressed |
| Teriflunomide | Teriflunomide | 19 | suppressed |
| Topiramate Er | Topiramate | 19 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 18 | suppressed |
| Meloxicam | Meloxicam | 17 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 17 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 15 | suppressed |
| Horizant | Gabapentin Enacarbil | 15 | suppressed |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 15 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 15 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 14 | suppressed |
| Betaseron | Interferon Beta-1b | 13 | suppressed |
| Diclofenac Potassium | Diclofenac Potassium | 13 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 13 | suppressed |
| Butalb-Acetaminoph-Caff-Codein | Butalbit/Acetamin/Caff/Codeine | 12 | suppressed |
| Oxtellar Xr | Oxcarbazepine | 12 | suppressed |
| Rufinamide | Rufinamide | 12 | suppressed |
| Tecfidera | Dimethyl Fumarate | 12 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 11 | suppressed |
| Dalfampridine Er | Dalfampridine | 11 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 11 | suppressed |
| Nabumetone | Nabumetone | 11 | suppressed |
| Phenobarbital | Phenobarbital | 11 | suppressed |
| Topamax | Topiramate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,062.90 · 48 records | Lilly USA, LLC | ACTHAR, AMYVID, Apokyn, BOTOX, BRIUMVI, Bafiertam, CREXONT, EPIDIOLEX, FYCOMPA, KISUNLA, NUPLAZID, Ocrevus Zunovo, QULIPTA, TRUDHESA, TYSABRI, UBRELVY, ULTOMIRIS, VALTOCO, VRAYLAR, VUMERITY, VYALEV, VYVGART, WAKIX, ZEPOSIA, ZTLido | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Fycompa play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error